November 21, 2026
$RichWire Markets and money, explained simply
LIVE
Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results

SELLAS Shares Surge Following Positive Phase 3 Leukemia Vaccine Trial Results

🧠 AI Analysis 2 min read 👁 5

SELLAS Life Sciences stock tripled, reaching a new 52-week high after reporting that its experimental cancer vaccine reduced the risk of death in acute myeloid leukemia patients by 41%.

SELLAS Shares Surge Following Positive Phase 3 Leukemia Vaccine Trial Results🧠AI Analysis

Photo: Benzinga

Key points

  • SELLAS shares jumped 183.13% to a 52-week high of $21.14 on Tuesday.
  • The Phase 3 REGAL trial met its primary endpoint, cutting the risk of death by 41%.
  • Median overall survival reached 24.0 months for vaccine recipients versus 14.7 months for control treatments.
  • The company targets a Biologics License Application submission in the first half of 2027.

Stock Skyrockets on Trial Data

Shares of SELLAS Life Sciences Group Inc. surged 183.13% to trade at $21.14 on Tuesday, touching a fresh 52-week peak. Trading activity spiked dramatically, with session volume reaching 57.567 million shares compared to a typical daily average of roughly 6.897 million.

The drastic equity move followed the release of topline data from the pivotal randomized Phase 3 REGAL clinical study. The trial assessed galinpepimut-S, an immunotherapy vaccine intended for acute myeloid leukemia patients who had achieved remission following previous salvage therapy but could not undergo a stem cell transplant.

Survival Metrics and Safety

According to the company, the late-stage evaluation successfully hit its main endpoint by demonstrating a statistically significant boost in overall survival. Treatment with the vaccine lowered the risk of mortality by 41%, registering a hazard ratio of 0.59 and a two-sided p-value of 0.035.

Patients administered the immunotherapy achieved a median overall survival duration of 24.0 months, outperforming the control cohort receiving the best available treatment, who recorded 14.7 months. The vaccine maintained a favorable safety profile aligned with historical clinical findings, displaying no unexpected adverse events.

Regulatory Plans

Following the successful trial outcome, the biopharmaceutical firm intends to consult with federal regulators regarding an expedited approval pathway. Management aims to submit a Biologics License Application during the first half of 2027.

What to watch next: Upcoming discussions between SELLAS management and federal health regulators regarding the planned 2027 Biologics License Application submission.

Source Benzinga — benzinga.com/trading-ideas/movers/26/11/63344384/sellas-stock-tripl… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.